Zenabis partners with Farmako to supply mass produced CBD isolate in Canada and medical cannabis to Germany

Zenabis Global Inc. (TSXV: ZENA)("Zenabis" or the "Company") is pleased to announce that it has entered into a binding term sheet for a three-year supply arrangement with leading German pharmaceutical research company Farmako GmbH ("Farmako") for: (1) the supply of biosynthetically produced pure CBD isolate oil (99.9%) from Farmako to Zenabis for sale in Canada; and (2) the supply of European Union Good Manufacturing Practices ("EU GMP") certified cannabis cultivated in Zenabis' indoor facilities in Canada for sale by Farmako to the German medical market.


Aurora Cannabis and Aphria Inc. to supply medical marijuana in Germany

Two Canadian cannabis producers, Aurora Cannabis (TSX:ACB) and Aphria Inc. (TSX:APHA), have been awarded contracts by the German government to cultivate and distribute medical marijuana throughout the European country.

Both companies say the decision by Germany's Federal Institute for Drugs and Medical Devices is provisional and subject to a mandatory 10-day waiting period, which allows unsuccessful bidders to submit a challenge before the final contract is signed.

If finalized, the cannabis produced by both Aurora and Aphria will supply the German medical marijuana market, which is the largest in Europe according to a recent report by market research firm Brightfield Group.


Cannabis producers in Canada and Germany are being put on hold

Two separate issues are plaguing these two big cannabis markets, but they have one thing in common: The government limiting the numbers of cannabis produced so that they somehow wouldn’t flood the streets with illegal cannabis.

Applicants aren’t transitioning

In the Canadian system, applicants trying to become cannabis producers are getting stuck in the limbo as they fail to transition to the new system.

According to HC, more than half of the cannabis site applications in Canada haven’t yet transitioned to the new licensing system.

As of December 31st, only 409 cannabis site applications in the queue to be cannabis cultivators had transitioned to the Cannabis Tracking and Licensing System.


Malta start-up angling for $10 million Canadian cannabis deal, refused letter of intent

Maricann, which has facilities in Germany and Canada, said it plans to use Malta for its finished dose products. The transaction is subject to Medican obtaining regulatory approval.

A Maltese start-up that attracted the interest of a Canadian medical producer for a $10 million deal for a letter of intent from Malta Enterprise, was rejected by the state investment arm.

Earlier last month, Canadian medical cannabis producer Maricann announced it was planning to acquire a Maltese start-up, Medican Holdings, for $10 million.

But the Maltese company was only formed in March 2018 and was then still not in possession of a letter of intent (LOI) from Malta Enterprise.


Lack of imports to help create cannabis shortage when Canadian recreational sales launch

International treaties, Health Canada ban on imports restrict supply from abroad.

Licensed cannabis producers are ramping up production to get ready for legalization of marijuana in Canada this year, but are also bracing for demand to far outstrip supply because of restrictions on imports.

Health Canada forbids licensed producers, which will be the only authorized sellers of marijuana to provincial governments, from importing any cannabis for sale, regardless of whether the purchase is for medical or recreational purposes.

The only cannabis imports that the department allows are those classified as genetic material for licensed dealers that conduct research and testing.


Syqe Medical develops device for measuring cannabis dose

CEO Perry Davidson:  We're a hardware company, a medical devices company, for administering medical cannabis.

The capital market has been swooning recently over listed cannabis companies, especially over the as yet unfulfilled promise of marketing the product overseas. Meanwhile, while approval for exporting cannabis is being delayed, quite a few less prominent private companies are starting to fulfill their promises in the Israeli market.


Aurora Cannabis Inc. (TSX:ACB): Could this be the best stock news release for the month?

The aggressively growing Canadian pot stock Aurora Cannabis Inc. (TSX:ACB) has been on a rampant acquisition spree this year with severely dilutive consequences for existing shareholders. The company has released a plethora of news pieces in May, starting with the conclusion of the CanniMed acquisition on May 1, and including the record breaking, high-profile, and evidently expensive MedReleaf Corp. (TSX:LEAF) acquisition at a huge premium. On top of the massive dilution, the massive growth in acquisitions “goodwill” on Aurora’s balance sheet, which highlights overpayments on acquired tangible assets, could be a recipe for disaster if this intangible asset has to be…


IGC unearthing pioneering Alzheimer’s treatment

India Globalisation Capital has been trialling a therapy that can restore memory in mice, promising potential for the treatment of Alzheimer’s.


How Big Pharma forces us to buy drugs instead of cannabis

Simply put, Big Pharma has been a long time opponent of legalizing medical marijuana as it threatens to ruin its business and drop the market cap for pharmaceutical drug companies.

Even though medical cannabis has been legalized in more than half of the US states, all of Canada and in Mexico, prices of drugs that could be replaced by cannabis are still on the rise.

Worse yet, prices of drugs that are made from the cannabis flower are being artificially inflated in places where medical marijuana is legal, but most recently in Germany of all places.

This is due to the fact that the Big Pharma has so far only competed with the black market when it comes to marijuana, but now all of that is starting to change.


Subscribe to RSS - Germany